Australia's most trusted
source of pharma news
Friday, 29 August 2025
Posted 28 August 2025 AM
In a move that bodes well for a TGA submission, Novo Nordisk has scored an FDA approval for Wegovy for a new indication.
The FDA has approved the GLP-1 RA for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, in combination with a reduced calorie diet and increased physical activity.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.